Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

Cardinal Health (NYSE:CAH) has been selected as a distributor for Telix Pharmaceuticals' Gozellix®, an important development ...

To support the rollout, Cardinal Health has deployed Telix’s ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, enabling standardized, high-efficiency and cost-effective production of ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial ...

Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging agent, Gozellix, by selecting Cardinal Health CAH as a key U.S. commercial ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...

We are pleased to be building upon our successful relationship to bring the accuracy and clinical utility of gallium-based imaging to even more patients across the country with Gozellix®.” ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.